Clinical trial · no report yet · Phase 3
LIBRETTO-531
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- NCT04211337 ↗
- Active not recruiting
- Loxo Oncology, Inc.
- 16 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 7 | |
| YouTube | 6 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Medullary Thyroid Cancer
- Interventions
- Selpercatinib; Cabozantinib; Vandetanib
- Arms
- Selpercatinib - Treatment A (TRT A) · Experimental
- Cabozantinib or Vandetanib - Treatment B (TRT B) · Active comparator
- Enrollment
- 291
- Primary outcomes
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
- Sponsor
- Loxo Oncology, Inc. with Eli Lilly and Company
- Start
- Feb 11, 2020
- Primary completion
- May 22, 2023
- Results posted
- Yes
- Registry record
- NCT04211337 · updated Mar 19, 2026
Publications
linked from the registry- Payakachat N, Gilligan AM, Altman D, Maeda P, Choi J, Bourke S, Speck RM, Spies E, Kopeckova K, Elisei R, Wadsley J, Krajewska J. Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5. J Geriatr Oncol. 2025 Sep;16(7):102304. doi: 10.1016/j.jgo.2025.102304. Epub 2025 Jul 4. PubMed 40617171
- Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient Rep Outcomes. 2024 Dec 19;8(1):149. doi: 10.1186/s41687-024-00823-8. PubMed 39694978
- Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. PubMed 37870969
- Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naive RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep;18(28):3143-3150. doi: 10.2217/fon-2022-0657. Epub 2022 Aug 15. PubMed 35969032
- Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1;28(5):540-546. doi: 10.1097/MED.0000000000000662. PubMed 34292174